Bioaffinity Technologies, Inc. (BIAF) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated September 17, 2023, details material definitive agreements and the completion of an asset acquisition by Bioaffinity Technologies, Inc. (the "Company"). The primary event is the acquisition of a clinical anatomic and clinical pathology laboratory in San Antonio, Texas, consummated on September 18, 2023, by the Company's wholly-owned subsidiary, Precision Pathology Laboratory Services LLC ("PPLS").
Key Financial Metrics and Transaction Details
The filing does not provide the Company's consolidated revenue, profit, or cash flow metrics for a specific reporting period. However, it discloses specific financial terms related to the acquisition and new obligations:
- Acquisition Consideration: Total consideration of $3,500,000 paid to Village Oaks Pathology Services, P.A. ("Village Oaks").
- Cash: $2,500,000.
- Equity: $1,000,000 paid via issuance of 564,972 shares of restricted common stock to the Joyce Living Trust (valued at $1.77/share).
- New Recurring Obligations (Assumed Leases & Contracts):
- Office Lease: $10,143.83 per month (5-year term).
- Hologic Equipment Lease: $16,914 per month minimum purchase commitment (expires Dec 2027).
- Leica Equipment Lease: $19,790 per month minimum purchase commitment (expires Mar 2026).
- Pathology Watch License: $63,000 per month total fee (digital imaging platform and support).
- Management Fee Structure: PPLS will pay Village Oaks a management fee equal to 70% of net revenues received by Village Oaks from medical services.
- Executive Compensation: Dr. Roby P. Joyce appointed as Medical Director/Laboratory Director with a base salary of $333,333.34 per year. Mr. Xavier Reveles promoted to COO with a base salary increase to $175,000 per year.
Material Changes and Agreements
The filing reports several material changes effective September 18, 2023:
- Asset Acquisition: PPLS acquired the Laboratory Assets of Village Oaks, including CLIA certification and CAP accreditation. Village Oaks retains ownership of the medical practice and provides interpretation services.
- Warrant Amendment: On September 17, 2023, holders of Tradeable, Non-Tradeable, and Pre-IPO Warrants consented to an amendment. These warrants are now non-exercisable until the Company files a certificate of amendment to increase authorized common stock to cover full exercise of all outstanding warrants.
- Corporate Governance: Dr. Roby P. Joyce was appointed to the Board of Directors. Mr. Xavier Reveles was appointed Chief Operating Officer.
- Long-Term Contracts: Execution of a 20-year Management Services Agreement and a 20-year Professional Services Agreement with Village Oaks, both with automatic renewal provisions.
Outlook, Risks, and Contingencies
Management Commentary and Strategy: The acquisition expands the Company's footprint in San Antonio and integrates a CAP-accredited, CLIA-certified laboratory. The structure separates the laboratory assets (owned by PPLS) from the medical practice (owned by Village Oaks), with PPLS providing management services for a 70% revenue share.
Risks and Contingencies:
- Succession Risk: A Succession Agreement mandates the automatic transfer of Dr. Joyce's equity in Village Oaks to a successor if he dies, becomes disabled, retires, or is disqualified from Medicare. The Company has the right to select the successor if the board's nominees are rejected.
- Financial Commitments: The Company has assumed significant fixed monthly costs for equipment leases and software licenses totaling approximately $110,000 per month, in addition to the office lease.
- Employment Termination: Dr. Joyce's employment agreement includes a "golden parachute" provision where he receives his base salary for the remainder of the three-year term if terminated for any reason (including death or notice), unless he breaches restrictive covenants (non-compete/confidentiality), in which case compensation is forfeited.
- Warrant Exercisability: Existing warrants cannot be exercised until the Company increases its authorized share count, creating a potential delay in liquidity for warrant holders.
Key Facts for Investor Verification
- Verify the pro forma financial impact of the $3.5M acquisition and the new ~$110k/month fixed operating costs on the Company's liquidity and cash burn rate.
- Confirm the status of the certificate of amendment to the Certificate of Incorporation required to make the amended warrants exercisable.
- Review the audited and unaudited financial statements of Village Oaks Pathology (Exhibits 99.1 and 99.2) to assess the revenue quality underlying the 70% management fee arrangement.
- Monitor the integration of the CyPath Lung license and the operational continuity of the laboratory under the new management structure.
- Assess the dilution impact of the 564,972 shares issued to the Joyce Living Trust.